Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19

被引：10
|
作者：
Chen, Junsen [1 ]
Huang, Rui [1 ]
Nie, Yiwen [1 ]
Wen, Xinyue [1 ]
Wu, Ying [1 ,2 ]
机构：
[1] Wuhan Univ, Sch Basic Med Sci, State Key Lab Virol, Wuhan 430072, Peoples R China
[2] Hubei Prov Key Lab Allergy & Immunol, Wuhan 430072, Peoples R China
来源：
VIROLOGICA SINICA | 2020年 / 35卷 / 06期
关键词：
COVID-19; mAbs; S glycoprotein; Epitopes; RESPIRATORY SYNDROME; STRUCTURAL BASIS; CORONAVIRUS; SARS-COV-2; NEUTRALIZATION; SPIKE; PNEUMONIA; PATIENT;
D O I：
10.1007/s12250-020-00327-x
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Coronavirus disease 2019 (COVID-19), reminiscent of the severe acute respiratory syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world. As there is no specific drug for COVID-19, neutralizing antibodies are attracting more and more attention as one of the most effective means to combat the pandemic. Here, we introduced the etiological and serological characteristics of COVID-19, discussed the current stage of development of human monoclonal antibodies against SARS-CoV-2 and summarized the antigenic epitopes in the S glycoprotein, which may deepen the understanding of the profile of immune recognition and response against SARS-CoV-2 and provide insight for the design of effective vaccines and antibody-based therapies.
引用
收藏
页码：713 / 724
页数：12
相关论文
共 50 条
  • [1] Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19
    Junsen Chen
    Rui Huang
    Yiwen Nie
    Xinyue Wen
    Ying Wu
    Virologica Sinica, 2020, 35 (06) : 713 - 724
  • [2] Databases for the targeted COVID-19 therapeutics
    Wang, Yunxia
    Li, Fengcheng
    Zhang, Ying
    Zhou, Ying
    Tan, Ying
    Chen, Yuzong
    Zhu, Feng
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (21) : 4999 - 5001
  • [3] Monoclonal Antibodies for COVID-19
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1642): : 16 - 16
  • [4] COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
    Michael Chary
    Alexander F. Barbuto
    Sudeh Izadmehr
    Marc Tarsillo
    Eduardo Fleischer
    Michele M. Burns
    Journal of Medical Toxicology, 2023, 19 : 205 - 218
  • [5] COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
    Chary, Michael
    Barbuto, Alexander F.
    Izadmehr, Sudeh
    Tarsillo, Marc
    Fleischer, Eduardo
    Burns, Michele M.
    JOURNAL OF MEDICAL TOXICOLOGY, 2023, 19 (2) : 205 - 218
  • [6] Human monoclonal antibodies as candidate therapeutics against emerging viruses
    Jin, Yujia
    Lei, Cheng
    Hu, Dan
    Dimitrov, Dimiter S.
    Ying, Tianlei
    FRONTIERS OF MEDICINE, 2017, 11 (04) : 462 - 470
  • [7] Human monoclonal antibodies as candidate therapeutics against emerging viruses
    Yujia Jin
    Cheng Lei
    Dan Hu
    Dimiter S. Dimitrov
    Tianlei Ying
    Frontiers of Medicine, 2017, 11 : 462 - 470
  • [8] Tackling COVID-19 with neutralizing monoclonal antibodies
    Corti, Davide
    Purcell, Lisa A.
    Snell, Gyorgy
    Veesler, David
    CELL, 2021, 184 (12) : 3086 - 3108
  • [9] Neutralizing monoclonal antibodies for treatment of COVID-19
    Taylor, Peter C.
    Adams, Andrew C.
    Hufford, Matthew M.
    de la Torre, Inmaculada
    Winthrop, Kevin
    Gottlieb, Robert L.
    NATURE REVIEWS IMMUNOLOGY, 2021, 21 (06) : 382 - 393
  • [10] Monoclonal Antibodies for Prevention and Treatment of COVID-19
    Marovich, Mary
    Mascola, John R.
    Cohen, Myron S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (02): : 131 - 132
12345